Adjuvant Treatment of Stage III Colon Cancer in Elderly Patients

Introduction to Capecitabine Monotherapy

The International Society of Geriatric Oncology (SIOG) recommends capecitabine as an appropriate chemotherapy regimen for adjuvant treatment of elderly patients with stage III colorectal cancer, provided that patients are given clear instructions about managing side effects and renal function guidelines are followed 1, 2
Capecitabine has been shown to be equally effective with comparable toxicity compared to bolus 5-FU/FA in patients ≥65 years in the X-ACT trial, which included patients up to 82 years of age 3, 4

Capecitabine monotherapy is an appropriate adjuvant treatment option for many elderly patients (≥70 years) with stage III colon cancer 1, 2
The American Society of Clinical Oncology and SIOG note that age alone should not exclude stage III colon cancer patients from consideration for adjuvant therapy, but comprehensive assessment of comorbidities and functional status is essential 3, 5

While XELOX (capecitabine plus oxaliplatin) and FOLFOX are considered standard treatment options for stage III colon cancer, their benefit is uncertain in patients aged >70 years 1, 6
SIOG guidelines note that the gains from adding oxaliplatin are modest, and most of the benefit is still conferred by the fluoropyrimidine component alone 1, 2
Oxaliplatin-based regimens are associated with significant long-term toxicity, particularly neuropathy that can persist for years after treatment completion 1

When using capecitabine in elderly patients, specific attention should be paid to renal function (dose adjustments may be necessary) 3, 4
Clear instructions about managing diarrhea should be provided to elderly patients receiving capecitabine 3, 7

Administering adjuvant chemotherapy for at least 5 months is important for efficacy in elderly colon cancer patients 3
Treatment decisions should be reached jointly by patient and physician, taking into account individual preferences and coexistent comorbidities 7, 5
For patients ≥80 years, the benefit of adjuvant chemotherapy may be smaller due to competing causes of death 3, 8

Undertreatment of elderly patients is common - studies show that only 40% of patients >80 years receive adjuvant chemotherapy despite evidence of benefit 8
Failing to adjust capecitabine dosing for renal impairment, which is common in elderly patients 3, 4
Not providing adequate education about managing common side effects like diarrhea, which can lead to unnecessary treatment discontinuation 7

The European Society for Medical Oncology recommends that all patients with stage III colon cancer should receive adjuvant chemotherapy unless significant contraindications exist 9, 10
Stage III disease (pT3N1) has a clear survival benefit from adjuvant treatment in elderly patients 11, 12

Single-agent fluoropyrimidine is the treatment of choice for most elderly patients 13, 9, 14
Capecitabine monotherapy is preferred over infusional 5-FU because it avoids central venous access complications 9, 14, 10
The American Society of Clinical Oncology recommends starting capecitabine at 80% dose reduction 13, 9
Capecitabine demonstrates equal efficacy with comparable toxicity versus bolus 5-FU/FA in patients ≥65 years 12

Oxaliplatin combination therapy (FOLFOX or XELOX) should be considered with extreme caution in highly selected fit elderly patients only 13, 9, 14
The European Society for Medical Oncology recommends that oxaliplatin combinations should not be routinely added in patients >70 years due to minimal to no survival benefit with increased toxicity 13, 9, 10

Adjuvant chemotherapy should be started between 3 weeks and maximum 8-12 weeks after surgery 13, 9, 14
Treatment should be continued for 6 months (12 cycles) 13, 9, 14

Renal function should be monitored closely, and dose adjustments are mandatory for renal impairment 12
The European Society for Medical Oncology recommends monitoring for clinically relevant neurotoxicity when using oxaliplatin 13, 9, 10

The recommendation for single-agent fluoropyrimidine over oxaliplatin combinations in elderly patients is based on Level I evidence from the MOSAIC trial and ESMO consensus guidelines 13, 9, 14